Table 1 Baseline demographics and characteristics of the patients with AS
Information | Kunxian (n = 35) | Placebo (n = 33) |
|---|---|---|
Demographics | ||
Male, n (%) | 32 (91.4) | 30 (90.9) |
Age, years (SD) | 27.19 (7.94) | 28.83 (7.09) |
Disease characteristics | ||
Symptom duration in years | 6.76 (5.47) | 7.98 (4.78) |
Concomitant NSAID, n (%) | 13 (37.1) | 15 (45.5) |
Clinical features, n (%) | ||
Inflammatory back pain | 32 (91.4) | 32 (97.0) |
Elevated CRP (>3 mg/liter) | 31 (88.6) | 24 (72.7) |
Elevated ESR (male >20; female >15 mm/h) | 32 (91.4) | 29 (87.9) |
Disease activity | ||
ASDAS-CRP | 3.36 (1.06) | 3.41 (1.00) |
BASDAI (0–10) | 4.79 (1.45) | 4.82 (1.22) |
Total back pain (0–10) | 5.09 (2.69) | 5.34 (2.58) |
Global assessment (0–10) | 5.18 (2.08) | 5.90 (1.85) |
Swollen joints, range 0–44 | 0.46 (1.48) | 0.29 (1.1) |
Tender joints, range 0–44 | 5.57 (4.96) | 4.91 (3.37) |
BASFI (0–10) | 3.10 (2.00) | 2.80 (2.00) |
Inflammation/morning stiffness (0–10) | 4.79 (2.79) | 5.2 (2.43) |
ESR (mm/h) | 36.95 (25.26) | 35.79 (31.46) |
CRP (mg/liter) | 29.5 (29.93) | 27.50 (29.69) |
BASMI (0–10) | 2.88 (1.95) | 3.75 (1.99) |